Copegus and Liver disorder - a phase IV clinical study of FDA data

Summary:

Liver disorder is reported as a side effect among people who take Copegus (ribavirin), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Pegasys, and have Depression.

The phase IV clinical study analyzes which people have Liver disorder when taking Copegus. It is created by eHealthMe based on reports of 15,097 people who have side effects when taking Copegus from the FDA, and is updated regularly.

What is Copegus?

Copegus has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 15,115 Copegus users. Check the latest studies of Copegus.

What is Liver disorder?

Liver disorder (liver diseases) is found to be associated with 1,732 drugs and 2,047 conditions by eHealthMe. Check the latest studies of Liver disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

15,097 people reported to have side effects when taking Copegus.
Among them, 66 people (0.44%) have Liver disorder.

Among these 66 people:

How long have people been on Copegus when they have Liver disorder? *

What is the gender of people who have Liver disorder when taking Copegus? *

female: 42.19 %
male: 57.81 %

What is the age of people who have Liver disorder when taking Copegus? *

What are other drugs people take besides Copegus? *

What are other side effects people have besides Liver disorder? *

Fatigue (feeling of tiredness): 19 people, 28.79%
Thrombocytopenia (decrease of platelets in blood): 12 people, 18.18%
Anaemia (lack of blood): 12 people, 18.18%
Abdominal Pain Upper: 11 people, 16.67%
Diarrhea: 11 people, 16.67%
Malaise (a feeling of general discomfort or uneasiness): 10 people, 15.15%
Fever: 9 people, 13.64%
Joint Pain: 8 people, 12.12%
Pain: 8 people, 12.12%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 8 people, 12.12%

What are the existing conditions these people have? *

Depression: 4 people, 6.06%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 3 people, 4.55%
Asthma: 2 people, 3.03%
Hepatitis (inflammation of the liver): 1 person, 1.52%
Cardiac Disorder: 1 person, 1.52%
Cardiac Failure: 1 person, 1.52%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 1.52%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 1.52%
Diabetes: 1 person, 1.52%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 1.52%

* Approximation only. Some reports may have incomplete information.

Do you take Copegus and have Liver disorder?

- Check whether Liver disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Copegus:

Copegus (15,115 reports)

Liver disorder treatments and more:

Liver disorder (57,384 reports)

Browse all side effects of Copegus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Liver disorder:

Liver disorder (1,732 drugs)

Browse all the conditions that are associated with Liver disorder:

Liver disorder (2,047 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Copegus) and Copegus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.